These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32315118)

  • 1. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults.
    Insel PS; Donohue MC; Sperling R; Hansson O; Mattsson-Carlgren N
    Ann Clin Transl Neurol; 2020 May; 7(5):776-785. PubMed ID: 32315118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
    Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
    Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.
    Yaari R; Holdridge KC; Mancini M; Rafii MS; Case M; Battioui C; Sims JR; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):857-868. PubMed ID: 39044494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
    Van Hooren RWE; Riphagen JM; Jacobs HIL;
    Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Structural and Amyloid Correlates of Recovery From Semantic Interference in Cognitively Normal Individuals With or Without Family History of Late-Onset Alzheimer's Disease.
    Abulafia C; Loewenstein D; Curiel-Cid R; Duarte-Abritta B; Sánchez SM; Vigo DE; Castro MN; Drucaroff LJ; Vázquez S; Sevlever G; Nemeroff CB; Guinjoan SM; Villarreal MF
    J Neuropsychiatry Clin Neurosci; 2019; 31(1):25-36. PubMed ID: 30305005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
    Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widespread distribution of tauopathy in preclinical Alzheimer's disease.
    Schultz SA; Gordon BA; Mishra S; Su Y; Perrin RJ; Cairns NJ; Morris JC; Ances BM; Benzinger TLS
    Neurobiol Aging; 2018 Dec; 72():177-185. PubMed ID: 30292840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease.
    Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC
    Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
    Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
    Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
    Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
    Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease.
    Lim YY; Maruff P; Kaneko N; Doecke J; Fowler C; Villemagne VL; Kato T; Rowe CC; Arahata Y; Iwamoto S; Ito K; Tanaka K; Yanagisawa K; Masters CL; Nakamura A
    J Alzheimers Dis; 2020; 77(3):1057-1065. PubMed ID: 32925048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults.
    Insel PS; Mohlenhoff BS; Neylan TC; Krystal AD; Mackin RS
    JAMA Netw Open; 2021 Jul; 4(7):e2117573. PubMed ID: 34297074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.